Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Galena Biopharma, Inc.

WAYNE, Pa., March 19, 2014 /PRNewswire/ --Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Oregon on behalf of a class (the "Class") comprising all purchasers of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ: GALE) securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").

Ryan & Maniskas, LLP.

If you purchased shares of Galena and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/gale. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.

The Complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose that: (1) the Company hired a promoter - The DreamTeam Group - to boost Galena's share price; (2) the promoter posted misleading articles on Galena's behalf without properly disclosing its paid marketing relationship; and (3), as a result, the Company's statements were materially false and misleading at all relevant times.

On February 12, 2014, TheStreet.com published an article alleging that several articles touting Galena, which were posted on the SeekingAlpha.com website under the guise of different individual investors, were removed from the site after it was discovered that the articles were written by the same person, without disclosure of the paid marketing relationship to Galena. Then, on February 14, 2014, in a Company-issued press release, Galena admitted that it had paid The DreamTeam Group to promote its stock.

On March 18, 2014, Galena acknowledged that the United States Securities and Exchange Commission has opened an investigation into whether Galena misled its investors.

If you are a member of the class, you may, no later than May 5, 2014, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. To learn more about the class action process, please visit: www.rmclasslaw.com.

CONTACT:

Ryan & Maniskas, LLP


Richard A. Maniskas, Esquire


995 Old Eagle School Rd., Suite 311


Wayne, PA 19087


484-588-5516


877-316-3218


www.rmclasslaw.com/cases/gale


rmaniskas@rmclasslaw.com

Photo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

SOURCE Ryan & Maniskas, LLP

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.